Industry News

Featured News Articles:

READERS' SURVEY: ARE STRATEGIC ALLIANCES GOOD FOR THE CRO INDUSTRY?

Are strategic alliances a positive or a negative thing for the CRO industry as a whole? In light of PCT Europe this week, we invite you to comment...
Learn more

VENN ACQUIRES GERMAN CRO AND SAYS THERE'S MORE TO COME

Venn Life Sciences has broadened its global footprint with the acquisition of a German CRO and says it is looking for more growth opportunities...
Learn more

Perils and Pitfalls of in Vitro Drug Transporter Assays Common Mistakes to Avoid in Order to Improve Translation of Interaction Data to the Clinic

Since 2006, when the U.S. FDA published a draft guidance on drug interaction studies, it has expected new drug applications to include in vitro data on the interactions of new drug candidates with drug transporters...
Learn more

Cyprotex buys CeeTox to expand preclinical services biz 02-Jan-2014

Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business...
Learn more

The most influential people in biopharma today

Any industry that's undergoing as much change as biopharma is always looking for leadership...
Learn more

BioMarin and its patient coaches are ready to roll on Vimizim launch

BioMarin Pharmaceuticals ($BMRN) nabbed the FDA's blessing for Vimizim, the only drug ever approved to treat a rare enzyme disorder called Morquio A syndrome. That's the good news...
Learn more

‘Intimate partnerships’: Parexel President shares CRO trends for 2014 10-Feb-2014

In an exclusive interview, Parexel’s president told Outsourcing-Pharma.com small pharma is increasing demand for CROs, commercialisation services are growing, and strategic partnerships are changing.
Learn more

Selecting Strategic Partners – The Lilly Way

As VP of Lilly Research Laboratories’ (LRL) operations and LRL Europe, Andy Dahlem puts his reputation on the line every day. When Eli Lilly and Company implemented its new outsourcing strategy several years ago, he was tasked with implementing it. The transformation took Lilly from a fully-integrated pharmaceutical company (FIPCO) to a fully-integrated pharmaceutical network (FIPNET) with numerous external partners.
Learn more


Leave a Reply